Home
HelpTest Code MSFGN Fibrillary Glomerulonephritis Confirmation, Mass Spectrometry, Paraffin Tissue
Necessary Information
1. Preliminary pathology report and history are required.
2. A brief explanatory note, or consultative letter, is recommended.
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Formalin-fixed or B5-fixed, paraffin-embedded tissue block
Collection Instructions:
1. Do not send fixed tissue slides. Testing can only be done on paraffin-embedded tissue blocks.
2. Attach the green pathology address label included in the kit to the outside of the transport container.
Useful For
Diagnosing fibrillary glomerulonephritis
Testing Algorithm
A pathology consultation is typically not required. If the results of this test do not support the clinical findings, PATHC / Pathology Consultation may be added if appropriate, upon client approval.
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Fibrillary GN Confirm, LC MS/MSSpecimen Type
AMYLOIDSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| AMYLOID | Ambient (preferred) | ||
| Refrigerated | |||
Interpretation
An interpretation will be provided.
Clinical Reference
1. Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515-1523
2. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-4959
3. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003;63(4):1450-1461
4. Casanova S, Donini U, Zucchelli P, Mazzucco G, Monga G, Linke RP. Immunohistochemical distinction between amyloidosis and fibrillar glomerulopathy. Am J Clin Pathol. 1992;97(6):787-795
5. Rosenmann E, Eliakim M. Nephrotic syndrome associated with amyloid-like glomerular deposits. Nephron. 1977;18(5):301-308
6. Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep. 2017;3(1):56-64
7. Dasari S, Alexander MP, Vrana JA, et al. DnaJ Heat Shock Protein Family B Member 9 is a Novel Biomarker for Fibrillary GN. J Am Soc Nephrol. 2018;29(1):51-56
Day(s) Performed
Monday through Friday
Report Available
7 to 15 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542
88380
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MSFGN | Fibrillary GN Confirm, LC MS/MS | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| BA0389 | Interpretation | 59465-5 |
| BA0390 | Participated in the Interpretation | No LOINC Needed |
| BA0391 | Report electronically signed by | 19139-5 |
| BA0392 | Material Received | 81178-6 |
| BA0393 | Disclaimer | 62364-5 |
| BA0394 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.